What Happened

Lycia Therapeutics filed for a $227.8 million IPO, planning to sell 14.7 million shares at $16–$18 each. Net proceeds will fund multiple phase 2 studies: $80 million for LCA-0061 (food allergy), $70 million for LCA-0062 (food allergy), and $90 million for LCA-0321 (Graves' disease). The company had $148.1 million in cash as of mid-2025 and employs 31 full-time staff.

Who Is Affected

Lycia's small team—led by former NGM Biopharmaceuticals COO Aetna Wun Trombley—will need to rapidly scale clinical operations. Vendors offering CRO services, clinical trial management, regulatory compliance, and data analytics are directly impacted. Competitors like Novartis and Genentech (Xolair) face a new entrant aiming to improve upon IgE blockade with degradation technology.

Market Impact

• Lycia's IPO signals continued investor appetite for protein degrader platforms in autoimmune and allergic disease.
• Phase 2 studies will drive near-term spending on patient recruitment, site management, and biomarker analytics.
• If successful, LCA-0061 could disrupt the $4B+ food allergy treatment market currently dominated by Xolair.

What to Watch

Pipeline execution: Phase 1 data for LCA-0061 showed rapid IgE reduction with no safety signals—phase 2 results will be pivotal. Hiring velocity: Lycia will likely expand beyond its 31 employees, creating entry points for sales reps targeting clinical-stage biotechs. Competitor response: Novartis and Genentech may double down on next-gen IgE inhibitors.

Related coverage

• Novartis pays $575M upfront for Abogen's mRNA T-cell engager ABO2203
• Scholar Rock secures FDA approval for SMA treatment apitegromab (Isembyld)
• Bristol Myers cuts another 265 jobs tied to New Jersey headquarters
• Telix Acquires ITM in $1.65B Radiopharmaceutical Deal